ClearPoint Neuro Q3 revenue $5.1M (+13% YoY); reaffirms FY2022 guidance

ClearPoint Neuro, Inc.

2022-Q3 EPS reported -$0.50 revenue$15,377,000

Revenue of $5.1M, up 13% YoY; gross margin improved to 72% from 66%.
Cash and short-term investments $40.5M at Sept 30, 2022; reaffirms FY2022 revenue $21-22M.
Partner PTC's Upstaza gene therapy approved in EU; SmartFlow Neuro Cannula included in label.
Added ~50 biologics/drug delivery partners; installed record 10 new systems YTD.
FDA cleared ClearPoint Maestro Brain Model, Prism Neuro Laser Therapy, and navigation software v2.1.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ClearPoint Neuro, Inc. reported third quarter ended September 30, 2022 results: revenue $5.1 million. Guidance reaffirmed.

Period: third quarter ended September 30, 2022
Revenue: $5.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2022. Third Quarter Highlights • Reported quarterly revenue of $5.1 million, a 13% year-over-year increase; • Partner PTC Therapeutics’ gene therapy treatment Upstaza TM was granted full marketing authorization by the European Commission. Upstaza will be

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001285550-22-000076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.